We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo

Psychedelics and the Neurobiology of Fast-acting Antidepressants

15 Dec 2021 at 17:00 UTC

Published: Nov 16, 2021   
Psychedelics and the Neurobiology of Fast-acting Antidepressants

Who's speaking at this Webinar?

Alex Kwan, PhD
Associate Professor, Department of Psychiatry, Yale University

Depression is debilitating, yet treatment options are limited. Psychedelics have emerged as potentially impactful drugs with promise of long-lasting beneficial actions. As a result, there are growing efforts to optimize their use in the clinic and to develop next-generation psychedelics with improved pharmacological profiles. One major challenge, however, is that we still do not have a full understanding of how psychedelics work in the brain.

In this seminar, I will describe my lab’s work on fast-acting antidepressants. I will talk about experiments in animal models that have identified cell types and neural plasticity processes involved in ketamine and psilocybin’s actions. I will discuss how the biological insights may lead to novel circuit-level biomarkers, which are crucially needed to accelerate the search for new psychiatric drugs.

During this webinar we will discuss:

  • Ketamine and psilocybin's actions on neural plasticity processes.
  • Biological insights which may lead to novel circuit-level biomarkers.

Watch Now

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter